158 related articles for article (PubMed ID: 32133044)
1. Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma.
Boyé P; Floch F; Serres F; Segaoula Z; Hordeaux J; Pascal Q; Coste V; Courapied S; Bouchaert E; Rybicka A; Mazuy C; Marescaux L; Geeraert K; Fournel-Fleury C; Duhamel A; Machuron F; Ferré P; Pétain A; Guilbaud N; Tierny D; Gomes B
Oncotarget; 2020 Feb; 11(7):671-686. PubMed ID: 32133044
[No Abstract] [Full Text] [Related]
2. Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.
Tierny D; Serres F; Segaoula Z; Bemelmans I; Bouchaert E; Pétain A; Brel V; Couffin S; Marchal T; Nguyen L; Thuru X; Ferré P; Guilbaud N; Gomes B
Clin Cancer Res; 2015 Dec; 21(23):5314-23. PubMed ID: 26169968
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.
Brel V; Annereau JP; Vispé S; Kruczynski A; Bailly C; Guilbaud N
Biochem Pharmacol; 2011 Dec; 82(12):1843-52. PubMed ID: 21924246
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
Boyé P; Serres F; Floch F; Fournel-Fleury C; Tierny D
Vet Comp Oncol; 2021 Mar; 19(1):44-52. PubMed ID: 32643242
[TBL] [Abstract][Full Text] [Related]
5. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.
Bombarde O; Larminat F; Gomez D; Frit P; Racca C; Gomes B; Guilbaud N; Calsou P
Mol Cancer Ther; 2017 Oct; 16(10):2166-2177. PubMed ID: 28611105
[TBL] [Abstract][Full Text] [Related]
6. The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.
Mouawad F; Gros A; Rysman B; Bal-Mahieu C; Bertheau C; Horn S; Sarrazin T; Lartigau E; Chevalier D; Bailly C; Lansiaux A; Meignan S
Oral Oncol; 2014 Feb; 50(2):113-9. PubMed ID: 24290982
[TBL] [Abstract][Full Text] [Related]
7. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
8. Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.
Leblond P; Boulet E; Bal-Mahieu C; Pillon A; Kruczynski A; Guilbaud N; Bailly C; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Invest New Drugs; 2014 Oct; 32(5):883-92. PubMed ID: 25008900
[TBL] [Abstract][Full Text] [Related]
9. Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.
Boyé P; Serres F; Marescaux L; Hordeaux J; Bouchaert E; Gomes B; Tierny D
PLoS One; 2017; 12(5):e0177486. PubMed ID: 28505195
[TBL] [Abstract][Full Text] [Related]
10. Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.
Ballot C; Jendoubi M; Kluza J; Jonneaux A; Laine W; Formstecher P; Bailly C; Marchetti P
Apoptosis; 2012 Apr; 17(4):364-76. PubMed ID: 22127645
[TBL] [Abstract][Full Text] [Related]
11. F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.
Thibault B; Clement E; Zorza G; Meignan S; Delord JP; Couderc B; Bailly C; Narducci F; Vandenberghe I; Kruczynski A; Guilbaud N; Ferré P; Annereau JP
Cancer Lett; 2016 Jan; 370(1):10-8. PubMed ID: 26404751
[TBL] [Abstract][Full Text] [Related]
12. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.
Kruczynski A; Vandenberghe I; Pillon A; Pesnel S; Goetsch L; Barret JM; Guminski Y; Le Pape A; Imbert T; Bailly C; Guilbaud N
Invest New Drugs; 2011 Feb; 29(1):9-21. PubMed ID: 19777159
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
Rusk A; Cozzi E; Stebbins M; Vail D; Graham J; Valli V; Henkin J; Sharpee R; Khanna C
Clin Cancer Res; 2006 Dec; 12(24):7456-64. PubMed ID: 17189419
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
17. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
18. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Wilson WH; Bates SE; Fojo A; Bryant G; Zhan Z; Regis J; Wittes RE; Jaffe ES; Steinberg SM; Herdt J
J Clin Oncol; 1995 Aug; 13(8):1995-2004. PubMed ID: 7636540
[TBL] [Abstract][Full Text] [Related]
19. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
20. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]